Roche Holding's chemotherapy drug Xeloda appeared to double the risk of death or relapse compared with intravenous chemotherapy in older women who had surgery to remove breast cancer tumors, according to a study. The results indicate that Xeloda "should not be used in an early-stage setting" in female patients 65 and older, the study's lead author said.

Full Story:

Related Summaries